Post-allograft transplant antirejection regimens (glucocorticoids, azathioprine, mycophenolate, calcineurin inhibitors and mTOR inhibitors) may trigger or aggravate hyperglycemia or hyperlipidemia. The gene discussed is MTOR; the disease is hyperlipidemia.